ClinicalTrials.gg
CompletedNCT04430855Updated Feb 6, 2023Results posted

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

A Phase 2 interventional study of Upadacitinib and Placebo in Hidradenitis Suppurativa (HS), sponsored by AbbVie. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.

Enrollment
9th of 11
68 · median 243
Started
2020
the only one that year
Phase 2
4 of 18
1 open now
Registered
13th of 18
by date

Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 4 in phase 2, and was the 13th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hidradenitis Suppurativa by AbbVie, or all of them as a file.
02

Study summary

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa in adult participants with moderate to severe disease. The study will assess change in disease signs and symptoms.

Read the detailed description

Upadacitinib is an investigational drug being developed for the treatment of HS. This study is "double-blinded," which means that neither the trial participants nor the study doctors will know who will be given study drug and who will receive placebo (no medicine). Participants are randomly (by chance) put into 1 of 2 groups, called treatment arms. They are randomized in a 2 to 1 ratio meaning more participants have a chance to receive upadacitinib compared to placebo.

Participants will undergo approximately 35-days of screening followed by a 48-week treatment period and a 30-day follow-up visit after the last dose of study drug for a total study duration of up to 57 weeks. The treatment period will consist of a 12-week placebo-controlled, double-blind period (Period 1) and a 36-week blinded extension period (Period 2).

There may be a higher burden for participants in this trial compared to their standard of care. Participants will attend visits every other week, once a month, or once every 2 months during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Hidradenitis Suppurativa (HS)

Keywords

  • Hidradenitis suppurativa (HS)
  • Upadacitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline.
  • Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline, presence of HS lesions in at least 2 distinct anatomical areas, and draining fistula count of ≤ 20 at Baseline.
  • History of inadequate response or an intolerance to adequate trial of oral antibiotics for treatment of HS.
  • Required to use a daily antiseptic wash on HS lesions.

Exclusion criteria

Exclusion Criteria:

-History of active skin disease (other than HS) that could interfere with assessment of HS, including skin infections requiring systemic treatment within 4 weeks of the Baseline visit.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Upadacitinib 30 mg

    Participants will receive 30 mg upadacitinib orally once a day for 12 weeks (Period 1) followed by 30 mg upadacitinib orally once a day for 36 weeks (Period 2).

    Drug: Upadacitinib

  • Experimental
    Placebo followed by Upadacitinib 15 mg

    Participants will receive matching placebo orally once a day for 12 weeks (Period 1) followed by 15 mg upadacitinib orally once a day for 36 weeks (Period 2).

    Drug: Upadacitinib · Drug: Placebo

Interventions

  • Tablet; Oral

    Also known as: RINVOQ

  • DrugPlacebo

    Tablet; Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

    HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage of Participants Achieving PGA Skin Pain Numeric Rating Scale 30 (NRS30) Response at Week 12 Among Participants With Baseline NRS ≥ 3

    The Patient's Global Assessment (PGA) of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. Participants were asked to rate their worst skin pain in the last 24 hours on an 11-point numerical rating scale ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine) on a daily basis using an electronic diary. The weekly average score was calculated based on the daily scores from the 7 days prior to the visit (with non-missing values in 4 or more days of the 7 day period). NRS30 is defined as the percentage of participants who achieved at least a 30% reduction and at least 1 unit reduction from Baseline in the PGA of skin pain NRS in participants with Baseline skin pain NRS ≥ 3.

    Time frame: Baseline and Week 12

07

Results

Posted Feb 6, 2023

Participant flow

Participants were enrolled at 21 study sites in 3 countries (Canada, Japan, and United States/Puerto Rico).

Period 1 (Weeks 1-12)
Participant flow — Period 1 (Weeks 1-12)
MilestonePlacebo / Upadacitinib 15 mgUpadacitinib 30 mg
Started2147
Received study drug2147
Completed1941
Not completed26
Withdrew: Adverse event10
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up02
Withdrew: Lack of efficacy01
Withdrew: Other01
Period 2 (Weeks 12-48)
Participant flow — Period 2 (Weeks 12-48)
MilestonePlacebo / Upadacitinib 15 mgUpadacitinib 30 mg
Started1941
Completed1431
Not completed510
Withdrew: Withdrawal by subject25
Withdrew: Lost to follow-up12
Withdrew: Lack of efficacy23

Outcome measures

PrimaryPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to Baseline.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
percentage of participantsPlaceboUpadacitinib 30 mg
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 1223.8 (5.6 to 42.0)38.3 (24.4 to 52.2)
Statistical analysis
  • Upadacitinib 30 mg · Chi-squared · p = 0.018 · Response rate difference: 13.3 · 95% CI -0.6 to 27.2Response rate difference compared to historical placebo = upadacitinib 30 mg - historical placebo
  • Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.142 · Adjusted response rate difference: 9.2 · 95% CI -7.6 to 25.9Response rate difference = upadacitinib 30 mg - placebo (in-trial + synthetic)
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.087 · Adjusted response rate difference: 14.7 · 95% CI -6.6 to 36.0Response rate difference = upadacitinib 30 mg - placebo
SecondaryPercentage of Participants Achieving PGA Skin Pain Numeric Rating Scale 30 (NRS30) Response at Week 12 Among Participants With Baseline NRS ≥ 3

The Patient's Global Assessment (PGA) of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. Participants were asked to rate their worst skin pain in the last 24 hours on an 11-point numerical rating scale ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine) on a daily basis using an electronic diary. The weekly average score was calculated based on the daily scores from the 7 days prior to the visit (with non-missing values in 4 or more days of the 7 day period). NRS30 is defined as the percentage of participants who achieved at least a 30% reduction and at least 1 unit reduction from Baseline in the PGA of skin pain NRS in participants with Baseline skin pain NRS ≥ 3.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PGA Skin Pain Numeric Rating Scale 30 (NRS30) Response at Week 12 Among Participants With Baseline NRS ≥ 3
percentage of participantsPlaceboUpadacitinib 30 mg
Percentage of Participants Achieving PGA Skin Pain Numeric Rating Scale 30 (NRS30) Response at Week 12 Among Participants With Baseline NRS ≥ 333.3 (6.7 to 60.0)36.4 (20.0 to 52.8)
Statistical analysis
  • Upadacitinib 30 mg · Chi-squared · p = 0.028 · Response rate difference: 13.9 · 95% CI -2.5 to 30.3Response rate difference compared to historical placebo (upadacitinib 30 mg - historical placebo)
  • Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.323 (Cochran-Mantel-Haenszel test adjusted for strata (Baseline Hurley Stage \[Stage \< III, Stage III\] and prior TNF use \[Yes or No\])) · Adjusted response rate difference: 4.5 · 95% CI -14.6 to 23.5Response rate difference = upadacitinib 30 mg - placebo (in-trial + synthetic)
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.421 · Adjusted response rate difference: 2.2 · 95% CI -19.6 to 24.0Response rate difference = upadacitinib 30 mg - placebo

Adverse events

Collected over Period 1: From first dose of study drug up to the first dose of study drug during Period 2 (12 weeks). Period 2: From first dose of study drug in Period 2 up to 30 days after the last dose of study drug (maximum of 40 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Placebo0/21 (0%)0/21 (0%)6/21 (28.6%)
Period 1: Upadacitinib 30 mg0/47 (0%)3/47 (6.4%)12/47 (25.5%)
Period 2: Upadacitinib 15 mg0/19 (0%)0/19 (0%)10/19 (52.6%)
Period 2: Upadacitinib 30 mg0/41 (0%)5/41 (12.2%)12/41 (29.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mgPeriod 2: Upadacitinib 30 mg
CHOLECYSTITISHepatobiliary disorders0/210/470/191/41
CELLULITISInfections and infestations0/210/470/191/41
ADJUSTMENT DISORDERPsychiatric disorders0/210/470/191/41
DEPRESSIONPsychiatric disorders0/210/470/191/41
SUICIDAL BEHAVIOURPsychiatric disorders0/210/470/191/41
SUICIDAL IDEATIONPsychiatric disorders0/210/470/191/41
SKIN PLAQUESkin and subcutaneous tissue disorders0/210/470/191/41
HYPOTENSIONVascular disorders0/210/470/191/41
COVID-19 PNEUMONIAInfections and infestations0/211/470/190/41
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/211/470/190/41
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mgPeriod 2: Upadacitinib 30 mg
HIDRADENITISSkin and subcutaneous tissue disorders0/210/473/193/41
DERMATITISSkin and subcutaneous tissue disorders3/210/471/190/41
HEADACHENervous system disorders0/215/472/192/41
NECK PAINMusculoskeletal and connective tissue disorders0/210/472/190/41
CELLULITISInfections and infestations2/210/470/190/41
MYALGIAMusculoskeletal and connective tissue disorders2/211/470/191/41
ACNESkin and subcutaneous tissue disorders1/211/470/193/41
URINARY TRACT INFECTIONInfections and infestations0/213/470/192/41
DIZZINESSNervous system disorders0/213/470/190/41
ABDOMINAL PAIN UPPERGastrointestinal disorders0/210/471/190/41

Baseline characteristics

The Intent-to-treat (ITT) population includes all randomized participants

Age, Continuous
Age, Continuous(years)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
Mean36.6 ± 12.4936.7 ± 11.7036.6 ± 11.85
Age, Customized
Age, Customized(Participants)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
< 40 years152944
40 - < 65 years51722
≥ 65 years112
Sex: Female, Male
Sex: Female, Male(Participants)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
Female163753
Male51015
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
Hispanic or Latino5914
Not Hispanic or Latino163854
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
American Indian or Alaska Native011
Asian336
Native Hawaiian or Other Pacific Islander000
Black or African American71219
White113041
More than one race011
Unknown or Not Reported000
Prior Exposure to Tumor Necrosis Factor (TNF) Antagonists
Prior Exposure to Tumor Necrosis Factor (TNF) Antagonists(Participants)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
Yes61218
No153550
Hurley Stage
Hurley Stage(Participants)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
Stage I101
Stage II112435
Stage III92332
Duration of Hidradenitis Suppurativa (HS) Disease
Duration of Hidradenitis Suppurativa (HS) Disease(years)Placebo / Upadacitinib 15 mgUpadacitinib 30 mgTotal
Mean9.83 ± 4.99011.52 ± 9.40111.00 ± 8.290

6 further baseline measures are reported on the registry.

08

Study locations

26 sites
  • Medical Dermatology Specialist /ID# 221084
    Phoenix, Arizona 85006-2722, United States
  • University of Arkansas for Medical Sciences /ID# 218404
    Little Rock, Arkansas 72205, United States
  • Medderm Associates /ID# 218317
    San Diego, California 92103, United States
  • Skin Care Research - Boca Raton /ID# 218809
    Boca Raton, Florida 33486-2269, United States
  • Lakes Research, LLC /ID# 218854
    Miami, Florida 33014, United States
  • ForCare Clinical Research /ID# 218013
    Tampa, Florida 33613-1244, United States
  • Northshore University Health System Dermatology Clinical Trials Unit /ID# 218319
    Skokie, Illinois 60077, United States
  • Dawes Fretzin, LLC /ID# 218310
    Indianapolis, Indiana 46256, United States
  • Beth Israel Deaconess Medical Center /ID# 218306
    Boston, Massachusetts 02215-5400, United States
  • Washington University-School of Medicine /ID# 218331
    Saint Louis, Missouri 63110, United States
  • Psoriasis Treatment Center of Central New Jersey /ID# 218330
    East Windsor, New Jersey 08520, United States
  • Duke Cancer Center /ID# 218526
    Durham, North Carolina 27710-3000, United States
  • University Hospitals Case Medical Center /ID# 218326
    Cleveland, Ohio 44106, United States
  • Southside Dermatology /ID# 218321
    Tulsa, Oklahoma 74132, United States
  • University of Pittsburgh MC /ID# 218329
    Pittsburgh, Pennsylvania 15260, United States
  • Medical University of South Carolina /ID# 218318
    Charleston, South Carolina 29425, United States
  • Duplicate_Center for Clinical Studies /ID# 218307
    Houston, Texas 77004, United States
  • Dermatology Specialists of Spokane /ID# 218760
    Spokane, Washington 99202, United States
  • Dermatology Research Institute Inc. /ID# 218780
    Calgary, Alberta T2J 7E1, Canada
  • Winnipeg Clinic /ID# 218963
    Winnipeg, Manitoba R3C 0N2, Canada
  • Dr. Wei Jing Loo Medicine Prof /ID# 218779
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc. /ID# 218778
    Markham, Ontario L3P 1X2, Canada
  • Takagi Dermatology Clinic /ID# 218587
    Obihiro-shi, Hokkaido 080-0013, Japan
  • University Hospital Kyoto Prefectural University of Medicine /ID# 220859
    Kyoto-shi, Kyoto 602-8566, Japan
  • Toranomon Hospital /ID# 218588
    Minato-ku, Tokyo 105-8470, Japan
  • Cruz-Santana, Carolina, PR /ID# 221188
    Carolina, 00985, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Apr 2021, 9 months.

Results were first posted in Feb 2023, 1 year 9 months after primary completion. A results delay was requested in Mar 2022.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 9 months is below that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2020
First posted
Jun 12, 2020
StartActual
Jul 14, 2020
Primary completionActual
Apr 22, 2021
CompletionActual
Jan 25, 2022
Results delay requested
Mar 22, 2022
Results first posted
Feb 6, 2023
Last update
Feb 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04430855
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Jul 14, 2020
Primary completion
Apr 22, 2021
Completion
Jan 25, 2022
Results posted
Feb 6, 2023
Last update
Feb 6, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion